New drug enatumab tested for tough blood disorder
NCT ID NCT07190261
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a drug called enatumab in 3 adults with relapsed or refractory warm antibody autoimmune hemolytic anemia (wAIHA), a condition where the immune system destroys red blood cells. Current treatments often stop working or cause relapses. Enatumab is given as injections over several weeks to see if it can control the disease. The main goal is to measure how many patients respond to treatment at 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enatumab
What this could lead to
If successful, enatumab could offer a new treatment option for people with relapsed or refractory warm antibody autoimmune hemolytic anemia, potentially reducing relapses and improving quality of life.
What could go wrong
This is a very small early-phase trial with only 3 participants, so results may not apply broadly. The drug may not work or could cause side effects, and larger studies are needed to confirm any benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••